Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pyxis Oncology, Inc. (PYXS) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Pyxis Oncology, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1782223.
Total stock buying since 2021: $17,743,268.
Total stock sales since 2021: $5,406,040.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 88,850 | $175,923 | 0 | $0 | 0 | $0 |
| 2023 | 1,853,020 | $5,073,437 | 36,558 | $81,469 | 0 | $0 |
| 2022 | 0 | $0 | 1,745,761 | $5,324,571 | 0 | $0 |
| 2021 | 788,200 | $12,493,908 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-11 | 88,850 | $175,923 | 0 | $0 | 0 | $0 |
| 2023-09 | 41,426 | $73,438 | 36,558 | $81,469 | 0 | $0 |
| 2023-03 | 1,811,594 | $4,999,999 | 0 | $0 | 0 | $0 |
| 2022-04 | 0 | $0 | 1,745,761 | $5,324,571 | 0 | $0 |
| 2021-12 | 10,000 | $93,890 | 0 | $0 | 0 | $0 |
| 2021-11 | 15,700 | $200,018 | 0 | $0 | 0 | $0 |
| 2021-10 | 762,500 | $12,200,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-26 | Connealy Pamela Ann (CFO & COO) | Buy | 88,850 | 1.98 | 175,923 |
| 2023-09-28 | Connealy Pamela Ann (CFO and COO) | Buy | 8,000 | 1.87 | 14,960 |
| 2023-09-27 | Wadhane Jitendra (Chief Accounting Officer) | Buy | 2,500 | 1.87 | 4,675 |
| 2023-09-27 | Connealy Pamela Ann (CFO and COO) | Buy | 6,426 | 1.85 | 11,868 |
| 2023-09-25 | Wadhane Jitendra (Chief Accounting Officer) | Buy | 5,000 | 1.77 | 8,850 |
| 2023-09-25 | Connealy Pamela Ann (CFO and COO) | Buy | 12,000 | 1.67 | 20,040 |
| 2023-09-22 | Wadhane Jitendra (Chief Accounting Officer) | Buy | 2,500 | 1.74 | 4,350 |
| 2023-09-22 | Connealy Pamela Ann (CFO and COO) | Buy | 5,000 | 1.74 | 8,695 |
| 2023-09-18 | Sullivan Lara (President and CEO) | Sale | 8,541 | 2.10 | 17,936 |
| 2023-09-14 | Sullivan Lara (President and CEO) | Sale | 100 | 2.25 | 225 |
| 2023-09-13 | Sullivan Lara (President and CEO) | Sale | 3,000 | 2.27 | 6,815 |
| 2023-09-12 | Sullivan Lara (President and CEO) | Sale | 4,917 | 2.25 | 11,073 |
| 2023-09-11 | Sullivan Lara (President and CEO) | Sale | 20,000 | 2.27 | 45,420 |
| 2023-03-17 | Pfizer Ventures (us) Llc (10% Owner) | Buy | 1,811,594 | 2.76 | 4,999,999 |
| 2022-04-21 | Chin Mark (Other) | Sale | 1,745,761 | 3.05 | 5,324,571 |
| 2021-12-08 | Cline Darren S (Director) | Buy | 10,000 | 9.39 | 93,890 |
| 2021-11-18 | Civik Thomas (Director) | Buy | 15,700 | 12.74 | 200,018 |
| 2021-10-13 | Cormorant Private Healthcare Fund Iii Lp | Buy | 450,000 | 16.00 | 7,200,000 |
| 2021-10-13 | Chin Mark | Buy | 312,500 | 16.00 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of PYXS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Pyxis Oncology, Inc. (symbol PYXS, CIK number 1782223) see the Securities and Exchange Commission (SEC) website.